Highbridge Capital Management

HCM is a global alternative investment management firm launched in 1992. Since its inception, the company has developed a diversified investment platform that includes hedge funds, traditional investment management products and debt and private equity investments with longer-term holding periods. With over 300 employees, including almost 100 investment professionals, HCM manages approximately $21 billion of capital for some of the world's most prominent institutional investors, public and corporate pension funds, endowments, foundations and family offices.

Marc Creatore

COO and CFO

David Frey

Managing Director

Jason Hempel

Managing Director and Portfolio Manager

Arjun Menon

Managing Director

Max Franklin Roberts

Chief Risk Officer and Managing Director

Salveson, Blair Adam

CFO, Managing Director, Senior Vice President, Head of Financial Planning and Analysis and Member of the Board of Managers

Jonathan Segal

Portfolio Manager, Managing Director

19 past transactions

CompoSecure

Post in 2021
CompoSecure offers proprietary products and leading edge design capabilities to address sophisticated, high-security requirements in both the public and private sector.

Urgently

Debt Financing in 2021
Urgently is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data, AI, and machine-to-machine communication.

BigBear.ai

Post in 2021
BigBear.ai is a decision dominance serving the national defense and intelligence communities. The Company delivers high-end capabilities across the data and digital spectrum to deliver information superiority and decision support. BigBear.ai provides a comprehensive suite of solutions including artificial intelligence and machine learning, data science, advanced analytics, offensive and defensive cyber, data management, cloud solutions, digital engineering, and systems integration.

Lime

Convertible Note in 2021
Lime aims to provide a sustainable solution to the first- and last-mile transportation problems by helping people move around their cities in an affordable and convenient way while eliminating their carbon footprint. The company empowers future generations to change their behavior so they can save this planet together. From the electric scooter to the e-assist and pedal bike, experience the excitement of Lime’s smart mobility fleet.
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.
Quotient Biodiagnostics is focused on providing high quality, high value immunohematology products to hospitals and blood banks in the US. Through its wholly-owned subsidiary, Alba Bioscience, Quotient offers more than 30 years of research, development and manufacturing of transfusion diagnostics products that traditionally have been sold worldwide either directly or by other major transfusion companies.

Gamida Cell

Post in 2021
Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.
Protalix is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins through its ProCellEx® plant cell-based protein expression system. Using ProCellEx, Protalix is focused on the development and commercialization of a proprietary pipeline of novel and biosimilar proteins that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Protalix’s initial commercial focus is on complex therapeutic proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. Protalix is also advancing additional recombinant biopharmaceutical drug development programs, including a TNF inhibitor for inflammatory diseases. Protalix’s pipeline is led by ELELYSO™(taliglucerase alfa for injection), which received approval from the U.S. Food and Drug Administration on May 1, 2012. ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein. Protalix has partnered with Pfizer for worldwide development and commercialization of ELELYSO, excluding Israel, where Protalix has retained full rights. Marketing applications for taliglucerase alfa have been submitted for Europe, Israel, Brazil and Australia, with additional regulatory submissions in progress.

Inseego

Post in 2017
Inseego is a global provider of software-as-a-service and solutions for the Internet of Things. It sells its telematics solutions under the Ctrack brand, including its fleet management, asset tracking, and monitoring, stolen vehicle recovery, and usage-based insurance platforms. Inseego also sells business connectivity solutions and device management services through Novatel Wireless, Inc. and Feeney Wireless ("FW"). The company was founded in 1996 and is headquartered in San Diego, California.

Emergent Payments

Series C in 2013
Emergent Payments delivers optimized payment solutions in high growth markets. We help merchants and partners grow revenues and open new markets. The company is based in Palo Alto, California with development centers in North Carolina and Shanghai, as well as international offices in Luxembourg, India, China, South Korea, Brazil, Singapore, Malaysia, Nigeria, Bangladesh and Japan. The company sold its Digital Commerce platform (Live Gamer Elements) to Autodesk in 2014, in order to focus on its core payments technology and business. It rebranded as Emergent Payments in early 2015 and invested in the payments platform, team and operations in high growth international markets.

ACE*COMM

Private Equity Round in 2007
ACE*COMM Corporation provided operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Its OSS solutions were applicable to various networks that include wired, wireless, voice, data, multimedia, and Internet communications networks. ACE*COMM marketed and sold its solutions in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. It had strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. The company was founded in 1983 and was headquartered in Gaithersburg, Maryland.

EUSA Pharma

Venture Round in 2006
Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

EUSA Pharma

Venture Round in 2005
Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

BravoSolution

Venture Round in 2005
BravoSolution US provides on-demand supply management solutions to companies primarily in the United States and Europe. It offers various supply management software & services in areas, such as program management, spend analysis, eSourcing, contract management, and supplier performance management. The company was formerly known as Verticalnet Inc. and changed its name to BravoSolution US in January 2008. The company was incorporated in 1995 and is based in Malvern, Pennsylvania. As of January 25, 2008, BravoSolution US operates as a subsidiary of BravoSolution SpA.

Pharmacopeia

Venture Round in 2005
Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company's products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. Pharmacopeia has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Cranbury, New Jersey. As of December 23, 2008, Pharmacopeia, Inc. operates as a subsidiary of Ligand Pharmaceuticals Inc.

Lexar

Private Equity Round in 2005
For more than 20 years, Lexar has been a trusted leading global brand of memory solutions. Our award-winning lineup includes memory cards, USB flash drives, card readers, and solid-state drives. With so many options, it’s easy to find the right Lexar solution to fit your needs. All Lexar product designs undergo extensive testing in the Lexar Quality Labs, facilities with more than 1,100 digital devices, to ensure performance, quality, compatibility, and reliability. Lexar products are available worldwide at major retail and e-tail stores. For more information or support, visit www.lexar.com.

Strategic Data Corp

Series B in 2000
Strategic Data Corp. is an interactive technology company focused on optimizing the delivery of online advertising. Founded in 1999, SDC has specialized in developing display ad serving and yield-optimization technology that significantly increases the revenue for its clients. Currently, it operates as a subsidiary of Fox Interactive Media.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.